Progenics Pharmaceuticals Earnings: Everything You Must Know Now

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Progenics Pharmaceuticals Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.22 in the quarter versus EPS of $-0.39 in the year-earlier quarter.

Revenue: Decreased 0% to $2.23 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Progenics Pharmaceuticals Inc. reported adjusted EPS loss of $0.22 per share. By that measure, the company missed the mean analyst estimate of $-0.19. It beat the average revenue estimate of $1.71 million.

Quoting Management: There was no comment from the management.

Key Stats (on next page)…